Netarsudil
Last updated: February 8th, 2022
Summary of Evidence
Netarsudil vs Timolol
Netarsudil was noninferior to timolol in patients with baseline IOP <27 mm Hg and <30 mm Hg.(ROCKET-4, 2019) {Khouri AS, Serle JB, Bacharach J, Usner DW, Lewis RA, Braswell P, Kopczynski CC, Heah T. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study. Am J Ophthalmol. 2019 Aug;204:97-104.}
Netarsudil (od and bd dosing) was non-inferior to timolol in patients with maximum baseline IOP < 25 mm Hg.(ROCKET-1 and -2, 2018) {Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, Novack GD, Kopczynski CC. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018 Feb;186:116-127.}